文献速递造血干细胞移植与细胞治疗白血病

儿童急性白血病中无关供者与HLA单倍体相合α/β T细胞及B细胞清除造血干细胞移植的比较

Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia.
PubMed 文献 · Blood · 2018-10-22

该多中心回顾性分析纳入13个意大利中心2010至2015年移植的127例全合无关供者、118例不全合无关供者和98例αβ单倍体相合移植的急性白血病患儿,均于形态学缓解期接受清髓性预处理。αβ单倍体相合移植的急性和慢性移植物抗宿主病发生率显著低于无关供者移植,与不全合无关供者移植相比非复发死亡更低、无GVHD无复发生存更优。作者认为αβ单倍体相合移植是急性白血病儿童需要移植时的合适治疗选择,尤其当无全合无关供者时。

要点

  • αβ单倍体相合移植的II至IV度和III至IV度急性GVHD累积发生率分别为16%和0%,低于全合无关供者的35%和6%及不全合无关供者的44%和18%(P < .001)。
  • αβ单倍体相合移植的总体和广泛型慢性GVHD发生率显著更低(P < .01)。
  • 中位随访3.3年,全合无关供者、不全合无关供者和αβ单倍体相合移植的5年无白血病生存率分别为67%、55%和62%。

核心结论

  • αβ单倍体相合移植是急性白血病儿童需要移植时的合适治疗选择,尤其当无全合无关供者时。

研究设计与样本

  • 多中心回顾性分析,纳入13个意大利中心2010至2015年移植的127例全合无关供者、118例不全合无关供者和98例αβ单倍体相合移植的急性白血病患儿。
  • 所有患儿均于形态学缓解期接受清髓性预处理后移植。

主要发现

  • 植入失败在全合无关供者移植组和不全合无关供者移植组各为2%,在αβ单倍体相合移植组为2%。
  • 全合无关供者 vs 不全合无关供者移植的II至IV度急性GVHD累积发生率分别为35% vs 44%,III至IV度分别为6% vs 18%,αβ单倍体相合移植组分别为16%和0%(P < .001)。
  • 全合无关供者、不全合无关供者和αβ单倍体相合移植组分别有8例(6%)、32例(28%)和9例(9%)患者死于移植相关并发症。
  • 中位随访3.3年,全合无关供者、不全合无关供者和αβ单倍体相合移植组的5年无白血病生存概率分别为67%、55%和62%。
  • 全合无关供者、不全合无关供者和αβ单倍体相合移植组的慢性GVHD无复发生存概率分别为61%、34%和58%(P < .001)。

关键数值与推荐

  • 与不全合无关供者移植相比,αβ单倍体相合移植受者的非复发死亡累积发生率更低且慢性GVHD无复发生存更优(P < .001)。

临床怎么用

  • 作者认为αβ单倍体相合移植是急性白血病儿童需要移植时的合适治疗选择,尤其当无全合无关供者时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditionally, hematopoietic stem cell transplantation (HSCT) from both HLA-matched related and unrelated donors (UD) has been used for treating children with acute leukemia (AL) in need of an allograft. Recently, HLA-haploidentical HSCT after αβ T-cell/B-cell depletion (αβhaplo-HSCT) was shown to be effective in single-center studies. Here, we report the first multicenter retrospective analysis of 127 matched UD (MUD), 118 mismatched UD (MMUD), and 98 αβhaplo-HSCT recipients, transplanted between 2010 and 2015, in 13 Italian centers. All these AL children were transplanted in morphological remission after a myeloablative conditioning regimen. Graft failure occurred in 2% each of UD-HSCT and αβhaplo-HSCT groups. In MUD vs MMUD-HSCT recipients, the cumulative incidence of grade II to IV and grade III to IV acute graft-versus-host disease (GVHD) was 35% vs 44% and 6% vs 18%, respectively, compared with 16% and 0% in αβhaplo-HSCT recipients (P < .001). Children treated with αβhaplo-HSCT also had a significantly lower incidence of overall and extensive chronic GVHD (P < .01). Eight (6%) MUD, 32 (28%) MMUD, and 9 (9%) αβhaplo-HSCT patients died of transplant-related complications. With a median follow-up of 3.3 years, the 5-year probability of leukemia-free survival in the 3 groups was 67%, 55%, and 62%, respectively. In the 3 groups, chronic GVHD-free/relapse-free (GRFS) probability of survival was 61%, 34%, and 58%, respectively (P < .001). When compared with patients given MMUD-HSCT, αβhaplo-HSCT recipients had a lower cumulative incidence of nonrelapse mortality and a better GRFS (P < .001). These data indicate that αβhaplo-HSCT is a suitable therapeutic option for children with AL in need of transplantation, especially when an allele-matched UD is not available.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018. PMID: 30348653. doi:10.1182/blood-2018-07-861575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。